Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs. Recludix was named a 2024 Fierce ...
Meet SH2-132 (otherwise known as Sharpless 132)—a large emission nebula located between the border of the Cepheus and Lacerta constellations. If you’ve never heard of it before, as most haven’t, don’t ...
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced data will be presented at the ...
New research describes a large set of interactions (interactome) which maps the range of phosphotyrosine (pTyr)-dependent interactions with SH2 domains underlying insulin (Ins), insulin-like growth ...
Some Western Bay of Plenty residents are pragmatic about the traffic on State Highway 2 despite renewed frustration at congestion on the highway. A section of SH2 between Te Puna and Aongatete started ...
Recludix Pharma has launched with $60 million in series A funding to use DNA-encoded libraries to discover small-molecule drugs. The start-up’s focus is on inhibiting SH2 domains, protein structures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results